“…There is no standard of care for the treatment of ON in children with ALL, especially for the early stages; meanwhile HBO showed itself to be safe and effective in most patients even those dose immunocompromised or critical ill (35,36). Our preliminary experience in HBO (3 patients included in the present study and treated until 2014) suggested its implementation in our current treatment approach.…”